Keywords: USA, Health care reform, Biosimilars, Legislation, BIO, GPhA

BIO argues case for retaining “biosimilars” legislation in US health care reform package

Article | 03 November 2009

Print This

The USA’s Biotechnology Industry Organization (BIO) issued the following statement in response to a letter recently sent by the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in